Piras Sandra, Loriga Mario, Paglietti Giuseppe
Dipartimento Chimico Tossicologico, Università di Sassari, Italy.
Farmaco. 2002 Jan;57(1):1-8. doi: 10.1016/s0014-827x(01)01159-4.
Among a new series of 26 4-(3-substituted-2-quinoxalylamino)phenylacetates and 4-(3-substituted-2-quinoxalylamino)-phenylacetyl-L-glutamates, eight were selected at NCI for evaluation of their in vitro anticancer activity. The results obtained in comparison with the corresponding nor-compounds series seem to indicate that this type of homologation is not helpful.